FDA Approval of Obesity Drugs – A Difference in Risk-Benefit Perceptions

Podobne zapisy

• Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
  od: Desai, Bansri, i wsp.
  Wydane: (2019)
• FDA’s Benefit–Risk Framework for Human Drugs and Biologics: Role in Benefit–Risk Assessment and Analysis of Use for Drug Approvals
  od: Lackey, Leila, i wsp.
  Wydane: (2020)
• FDA Guidance and New Drug Approvals
  od: Walker, Scot
  Wydane: (2018)
• Overview of drugs approved by the FDA in 2022
  od: D. V. Kurkin, i wsp.
  Wydane: (2023-11-01)
• FDA APPROVES NEW HEMOPHILIA DRUG
  od: article Editorial
  Wydane: (2025-02-01)